Introduction
T cells integrate positive (1) and negative (2) inputs through activation-induced cell death (3) . Fas ligand (FasL; CD95L), which binds to Fas, is a member of the tumor necrosis factor a diverse set of surface receptors and associated signaling pathways. Co-stimulator receptors on T cells, when triggered superfamily and is expressed by a variety of immune cells, including monocytes, NK cells, and activated B and T cells in trans by antigen-presenting cell (APC) membrane-associated co-stimulators, enhance T cell receptor-dependent cellu-(4-6). FasL is a trimeric, type II membrane-associated protein (7,8) that is released as soluble FasL (sFasL) trimers from lar proliferation and cytokine secretion. Alternatively, inhibitory receptors on T cells, when triggered in trans by their cognate membranes by metalloproteinase cleavage (9-11). Several observations have prompted us to devise FasL inhibitors anchored on APC surfaces, induce T cell unresponsiveness and/or apoptosis. In devising strategies for inhibiting protein derivatives that can associate with cell membranes. Membrane-associated FasL induces apoptosis more effecpathogenic T cells, investigators have targeted both costimulatory and inhibitory pathways, using soluble recombintively than does sFasL (12-16), possibly stemming from the higher functional valency expected for membrane-associated ant proteins directed at one or the other. However, the possibility now emerges for combining within a single recomligands, as compared to their soluble forms. Indeed, experiments with different sFasL proteins support the notion that binant protein the capacities to simultaneously interface with both pathways.
FasL's functional valency dictates its potency. For example, whereas naturally processed, trimeric sFasL induces The Fas (CD95) receptor on T cell surfaces participates in were prepared by culturing cells for 5-6 days in Cellgro-FREE the chemical cross-linker dithiobis(succinimidyl proprionate) (DSP; Pierce) at room temperature for 30 min, prior to quenchsupplemented with penicillin/streptomycin and L-glutamine (Mediatech, Herndon, VA). Cellular debris was removed from ing with 0.1 M Tris base/0.1M glycine. Samples for SDS-PAGE analysis were prepared in Laemmli sample buffer, with cell culture supernatants by centrifugation (6 min at 400 g) followed by filtration through 0.2 µm sterile syringe filters.
or without 2-mercaptoethanol (2-ME), and were boiled prior to loading onto 10% SDS-PAGE gels. Following electrophoresis, Clarified supernatants were stored at 4°C for 2 months without significant loss of activity. A commercially available solidgels were blotted onto Immobilon P membranes (Millipore, Beverly, MA), blocked with 5% milk/PBS and probed with phase assay (MBL, Cambridge, MA) was used to quantitate sFasL in samples.
anti-human FasL antiserum (anti-C20; Santa Cruz Biologicals, Santa Cruz, CA). After extensive washing, blots were incubHuman peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers by Ficoll-Hypaque (Pharated with horseradish peroxidase-conjugated anti-rabbit antiserum (BioRad, Richmond, CA) and developed with enhanced macia Biotech, Uppsala, Sweden). Proliferation assays with human PBMC were performed in 96-well U-bottom tissue chemiluminescent substrate (NEN, Boston, MA) prior to exposure to X-ray film. culture plates. The assay medium consisted of R10 supplemented with 25 mM HEPES pH 7.4 (R10-H). Assays were Flow cytometry performed in triplicate. Purified CTLA-4-FasL (vide infra), CTLA-4-Ig (43) Cytotoxicity assays sequentially loaded with 100 µg of rabbit anti-mouse Ig and after washing, with 50 µg of the mouse anti-human FasL mAb Cytotoxicity assays were performed in triplicate as described (44) , with a few modifications. Jurkat cells in exponential NOK-1 (PharMingen, La Jolla, CA). After washing, antibodies were cross-linked to beads in 0.2 M sodium borate, pH 9.0, growth phase were labeled at 37°C for 4-5 h with 3 µCi/ml of [ 3 H]thymidine (ICN, Costa Mesa, CA) in R10 medium, pelleted with 5 mg/ml of dimethyl pimelimidate (Pierce, Rockford, IL). Chemical cross-linking reactions were quenched with 0.2 M and washed twice. Cells were resuspended in R10 at 2ϫ10 5 / ml, and 0.1 ml of the cell suspension was added to each ethanolamine, pH 8.0, for 2 h, and the beads were washed with PBS containing 0.05% sodium azide and then stored well. Clarified supernatants containing CTLA-4-FasL or β 2 mFasL were diluted into R10 and 0.1 ml of each diluted sample at 4°C.
Immunoaffinity purification of CTLA-4-FasL was performed was added to individual wells of round-bottom 96-well tissue culture plates. Anti-Flag mAb (Sigma) was added as crossin batches. An aliquot of 0.1 ml of the FasL-specific beads was added to cell culture supernatants containing CTLA-4-linker at 0.5 µg/ml to indicated samples. Pre-incubation of cells with defined quantities of CTLA-4-FasL or β 2 m-FasL FasL and rocked overnight at 4°C. Beads were collected by centrifugation and washed with 0.2 M sodium phosphate, pH was performed on ice for 1 h, followed by centrifugation (6 min at 400 g) and two washes with R10. In each experiment, 6.8. CTLA-4-FasL was batch-eluted from the beads with 0.1 M citrate, pH 2.5, and transferred into tubes containing 1 M a medium-only control was used to determine the spontaneous loss of radiolabeled DNA. For cell-cell killing assays, 10 4 prephosphate, pH 8.0, for neutralization. Purified CTLA-4-FasL was quantitated by the commercial sFasL solid-phase assay treated effector cells were added per well. Cultures were incubated for 17-20 h at 37°C and radiolabeled DNA was cited above.
then harvested onto glass filters for scintillation counting. In Gel filtration chromatography and Western blotting blocking experiments, Jurkat cells and supernatants to be blocked were pre-incubated with anti-Fas mAb (ZB4; Coulter For analyses of molecular size and stoichiometry, clarified cell culture supernatants containing CTLA-4-FasL were conImmunotech, Westbrook, ME) and anti-FasL mAb (NOK-1; PharMingen) respectively. Percent Fas-dependent specific centrated 15-to 30-fold with Centricon-10 ultrafiltration devices (Amicon, Beverly, MA). The retentate was applied to lysis was calculated according to the equation 100ϫ(S -E)/ S, where S and E represent retained DNA in the absence of a pre-calibrated Superdex-200 (Pharmacia Biotech) column in 1ϫPBS, and 0.5 ml fractions were collected and analyzed added protein and experimentally retained DNA in the presence of added protein respectively. Maximal killing ranged using a sFasL ELISA. Fractions containing active CTLA-4-FasL were concentrated 50-fold and then co-incubated with from 40 to 70%, depending on the assay.
Annexin V binding assays
Daudi cells (10 6 ) were pre-treated with 300 ng/ml of CTLA-4-FasL or β 2 m-FasL on ice for 1 h, pelleted and washed. Pre-treated Daudi cells (5ϫ10 5 ) were plated beneath semipermeable 3 µm membranes (Becton Dickinson) in 24-well tissue culture plates. Jurkat cells (10 6 ) were added either above or below the membrane, as indicated. After an 18 h incubation period, cells were pre-stained with CD3-FITC (Dako) and then tested for externalization of phosphatidylserine (used as a marker for early apoptosis), as detected by binding of Annexin V-phycoerythrin (PharMingen), according to the manufacturer's protocol. Propidium iodide-excluding populations of CD3 ϩ cells were gated for analysis, and Annexin V bright cells were counted and plotted as percent of total CD3 ϩ cells.
Results

Expression of CTLA-4-FasL and β 2 m-FasL fusion proteins
Two FasL-containing fusion proteins, CTLA-4-FasL and β 2 mFasL, were produced using chimeric coding sequences. The CTLA-4-FasL fusion protein, incorporating as its second component the ectodomain of human CTLA-4, was designed with dual functions in mind: (i) binding to, and thereby masking of, resident B7-1/B7-2 (CD80/CD86) on APC surfaces, and (ii) conferring pro-apoptotic trans signaling activity to APC (with the membrane-anchored FasL on APC signaling to the Fas receptor on responding T cells). β 2 m-FasL was developed as a FasL-containing, control fusion protein lacking the capacity to engage B7 proteins. These two fusion proteins were produced by stably transfecting the respective chimeric coding sequences, carried in EBV episomal expression vectors, into 293 human embryonic kidney cells (see Methods). The 293 cells were chosen for producing these FasL-containing fusion proteins since this cell line has been used previously with success for the expression of functional sFasL To confirm these gel-based CTLA-4-FasL multimerization (with a concomitant reduction in the lower mol. wt species) with higher concentrations of cross-linker (in the absence of findings, Superdex-200 gel filtration chromatography was performed. Peak column fractions containing FasL immunorereducing agent; Fig. 1B ). Partial reduction of the cross-linked (1 mM DSP) samples permitted the visualization of three activity, as determined by ELISA, eluted, as expected, at 140-150 kDa. Chemical cross-linking of peak fractions folmolecular species of~45,~70-90 and~140-150 kDa. The most straightforward interpretation for this pattern is that the lowed by anti-FasL immunoblotting also revealed the~70-90 and~140-150 kDa CTLA-4-FasL complexes (data not CTLA-4-FasL monomers (~45 kDa) are progressively crosslinked into dimeric (~70-90 kDa) and then trimeric (~140-shown). Hence, the chemical cross-linking and gel filtration analyses, taken together, suggest that CTLA-4-FasL com-150 kDa) complexes (Fig. 1B) . Of note, recombinant~26-29 kDa sFasL monomers were reported to migrate as~75 kDa plexes have a trimeric molecular stoichiometry, with the presence of intermolecular disulfide bridges between at least trimeric complexes by gel filtration chromatography (18). These findings, together with those of Fig. 1(A (Fig. 2A) . Importantly, the addition of Daudi also potentiated CTLA-4-FasL-mediated cytotoxicity (data not shown).
In addition, titrating the number of Daudi cells added to wells revealed a Daudi cell dose-dependent increase in Jurkat cell death (Fig. 2B) . The dependence of the observed cytotoxicity upon the FasL component within the CTLA-4-FasL fusion protein was established by demonstrating that killing could be reversed with the addition of either anti-Fas or anti-FasL blocking mAb (Fig. 2C) . No significant killing of Jurkat cells was detected with β 2 m-FasL alone over the range of 0.1-100 ng/ml, except in the presence of a cross-linking, epitope tag (Flag)-specific mAb (Fig. 2D) . Of note, similar results were obtained for both CTLA-4-FasL and β 2 m-FasL when Annexin V binding assays, which measure the externalization of phosphatidylserine as an early marker of apoptosis (45), were used as a readout (data not shown). Hence, B7 ϩ cells potentiate the ability of CTLA-4-FasL to signal in trans through Fas receptors on Jurkat cell targets.
Dependence of CTLA-4-FasL trans effector activity upon intercellular contact
CTLA-4-Ig binds to cells expressing B7-1 and/or B7-2 (46) . To test whether CTLA-4-FasL similarly binds to B7 ϩ cell surfaces, we incubated B7-1/B7-2 ϩ Daudi cells with increasing concentrations CTLA-4-FasL-containing cell supernatants and detected surface FasL expression by indirect immuno- fluorescence and flow cytometry. A CTLA-4-FasL dosesignificantly less inhibition. At higher concentrations of sFasL, dose-dependent inhibition was detected, reaching~43% at dependent increase in the detection of cell surface-associated FasL epitopes was observed, with a plateau at~100 ng/ml 1000 ng/ml (Fig. 4C) . Likewise, antibody cross-linked sFasL was inhibitory at higher concentrations (~77% inhibition at (Fig. 3A, upper panel) . In parallel, we demonstrated CTLA-4-FasL also binds to Fas ϩ (B7 -) Jurkat cells, with a dose-1000 ng/ml). Of note, in control assays, commercial sFasL that was maximally activated by antibody cross-linking demdependent increase in CTLA-4 epitopes upon adding 30-300 ng/ml of CTLA-4-FasL (Fig. 3A, lower panel) . Hence, CTLAonstrated quantitatively comparable apoptosis-inducing activity to cell-anchored CTLA-4-FasL (data not shown). 4-FasL exhibits the expected binding potentials for cells expressing either B7 or Fas at their surfaces.
The combination of sFasL (with and without cross-linking antibody) and CTLA-4-Ig was tested for inhibitory activity at Building upon the capacity of CTLA-4-FasL to bind to Daudi cell surfaces, these cells were pre-coated with CTLAthe peak of cellular proliferation (Fig. 4C) . Adding CTLA-4-4-Ig and sFasL in combination increased inhibition by up to 4-FasL and their apoptosis-inducing potential was evaluated. As shown in Fig. 3(B demonstrates potencies~1000-and~220-fold greater than CTLA-4-Ig and sFasL respectively. Antibody-cross-linking of and the Jurkat target cells were in direct contact on the same side of the semipermeable membrane (Fig. 3C, lower panel) ; sFasL increased inhibitory potency and reduced the IC 50 of sFasL to~5.7 nM (~5-fold). the Jurkat cells present in isolation above the membrane did not demonstrate Annexin V positivity (Fig. 3C, upper panel) .
Combining CTLA-4-Ig and sFasL lowered the doses required for inhibition, regardless of the presence of crossAs expected, no Jurkat cell apoptosis was observed when either untreated or β 2 m-FasL-treated Daudi cells were used linking antibodies. In calculating IC 50 s for these combinations, the IC 50 of sFasL was determined in the presence of a as effectors. This experiment clearly shows that once bound to B7 ϩ cells, CTLA-4-FasL function is cell-cell contact maximal dose of CTLA-4-Ig (10 µg/ml). The inhibition curves take into consideration the baseline offset observed in the dependent. Moreover, these dual-chamber experiments indicate that CTLA-4-FasL-coated cells do not shed sufficient presence of 10 µg/ml CTLA-4-Ig. IC 50 s (molar calculations based on the mol. wt of sFasL) for CTLA-4-Ig plus sFasL and CTLA-4-FasL protein, either through direct protein loss or microvesiculation, to induce apoptosis at a distance in Jurkat for CTLA-4-Ig plus antibody-cross-linked sFasL were~26 and~2.9 nM respectively. Taken together, findings indicate cell targets. Furthermore, the experiment rules out the possibility that the Daudi cells, once coated with CTLA-4-FasL, that CTLA-4-FasL's inhibitory capacity substantially exceeds that of CTLA-4-Ig and sFasL, whether used alone or in release some type of other soluble inhibitory factor that could act on its own.
combination.
Relative activity of purified CTLA-4-FasL versus CTLA-4-Ig against peripheral T cell responders Discussion
The immunomodulatory activity of CTLA-4-FasL was compared to that of CTLA-4-Ig and sFasL, the latter two proteins
In this report, we describe CTLA-4-FasL as a novel fusion protein that physically and functionally bridges APC and T corresponding to CTLA-4-FasL's component parts. For this experiment, peripheral T cells (within PBMC) were used in cells. The CTLA-4 component targets this fusion protein to APC surfaces and endows it with CTLA-4-Ig's well-documented place of the Jurkat T cell line, and the capacity of the various proteins in their purified forms to inhibit anti-CD3 mAb (OKT3)-potential to block B7 co-stimulation. However, unlike CTLA-4-Ig, CTLA-4-FasL incorporates a second functional induced proliferation of these T cells was assessed. As baseline data, graded doses of OKT3 mAb (from 0.1 to 1.0 component, FasL, that confers to it trans signaling (apoptosisinducing) potential. Thus, within CTLA-4-FasL, a solubilized ng/ml) yielded the expected increases in T cell proliferation (data not shown). CTLA-4-FasL potently inhibited this proliferco-stimulator receptor capable of blocking co-stimulation of T cells has been combined with a soluble derivative of a ative response at all time points (Fig. 4A) , with complete inhibition observed at 30 ng/ml CTLA-4-FasL at an OKT3 protein capable of inducing T cell apoptosis. Our data indicate that the CTLA-4-FasL fusion protein offers functional features concentration of 1 ng/ml (Fig. 4B) . In contrast, the addition of equivalent amounts of CTLA-4-Ig or sFasL resulted in that surpass those of its CTLA-4 and FasL components, during T cell activation. FasL is a type II membrane protein, i.e. its functional Membrane anchorage potentiates CTLA-4-FasL's apoptosis-inducing activity. This was directly demonstrated in C-terminus projects outward from the membrane (55). Previously, a variety of heterologous sequences have been experiments where B7 ϩ anchoring cells were either titrated into the killing assay or were pre-coated with the fusion protein appended to type II membrane proteins for purposes such as directing secretion, influencing multimerization and prior to the addition of target cells. The membrane anchorage effect likely reflects an augmentation of functional valency.
appending epitope tags (17,56-59). In the present study, we report a unique type of type II membrane protein derivative, Furthermore, the data and interpretation are consistent with the literature comparing the functional activities of membranein which the N-terminal intracellular and transmembrane domains of this protein have been replaced with a functional associated versus sFasL. For example, whereas 0.1 ng of neuro2A cell membrane preparations containing membranedomain that anchors it to cell surfaces. In the case of the CTLA-4-FasL fusion protein developed here, the CTLA-4 associated FasL readily kill Jurkat cells (13), 10-to 100-fold more recombinant, sFasL molecular aggregates derived from anchoring domain, derived from a type I membrane protein, confers an added functional feature, i.e. trans signal masking. COS cell transfectants are required to trigger significant Fasdependent cell death of mouse cell lines (17,47). CTLA-4-An elegant aspect of CTLA-4-FasL's design is that this chimeric soluble type I-type II protein positions the type II FasL's activity level contrasts with that of β 2 m-FasL, which does not detectably bind to APC surfaces and displays no component at the C-terminus, projecting this business end of the molecule away from the membrane following membrane significant cytocidal effects in the absence of cross-linking antibody. The enhancement of β 2 m-FasL function with epitope association. The observation that CTLA-4-FasL results in apoptosis of tag-specific cross-linking antibody parallels that documented for other recombinant sFasL trimers (13).
B7-1 -/B7-2 -Jurkat cells was unexpected, given that another trimeric sFasL derivative has been reported to function as an As an immunomodulator, CTLA-4-FasL combines CD28 antagonism with Fas receptor agonism. This particular comantagonist (11). One explanation for this finding revolves around the structure of CTLA-4-FasL. Based upon our gel bination was motivated by data pointing to an antagonistic relationship between the CD28 and Fas pathways. CD28
analyses, each CTLA-4-FasL trimer likely consists of two disulfide-linked CTLA-4 domains and an unpaired, 'free', signaling inhibits Fas-dependent apoptosis (48), possibly due to up-regulation of Bcl-x L (48,49). Furthermore, CD28 co-CTLA-4 domain. Hence, in principle, interactions between the free CTLA-4 domains of two CTLA-4-FasL trimers could occur. stimulator blockade inhibits survival pathway signaling (49) and thereby promotes the Fas apoptosis pathway (39) (40) (41) (42) .
Our chemical cross-linking data indicate soluble CTLA-4-FasL predominates in trimeric complexes, it is unlikely that One group has suggested that co-stimulator-induced cytoprotection from Fas-mediated apoptosis stems from FLIP/I-FLICE/ free CTLA-4 domains dimerize readily in solution. However, the fact that soluble CTLA-4-FasL kills Jurkat cells suggests FLAME-1/CASH/casper-mediated inhibition of death cascade signaling (50); however, this conclusion was not supported the possible dimerization of unpaired CTLA-4 domain units within cell surface-bound CTLA-4-FasL trimers. In principle, in another study (51) . In recent experiments, we have demonstrated B7-1:FasL antagonism by combining B7-1 and FasL this would yield CTLA-4-FasL 'hexamers' with proapoptotic activity analogous to that of antibody-cross-linked sFasL protein transfer (A. Chen and M. Tykocinski, unpublished observations). That said, the precise extent to which B7
hexamers. In support of this hypothesis, both CTLA-4-FasL and antibody-cross-linked β 2 m-FasL display similar doseblockade contributes to CTLA-4-FasL's observed activity remains unclear and will require more complicated experiresponse curves for Jurkat cell apoptosis (Fig. 1) . This CTLA-4-FasL hexamerization hypothesis will require further testing. mental approaches.
The onset of Fas-mediated, activation-induced cell death Targeting of pathogenic tissues with soluble, Fas-specific agents reveals a significant toxicity issue in vivo. Intraperiin peripheral human T cells, in vitro, occurs~4-5 days postactivation (52) . Hence, the observation that CTLA-4-FasL toneal or i.v. administration of either Fas-specific antibody (20) or recombinant sFasL (18,19) result in fulminant hepatitis, significantly inhibits T cell proliferation as early as culture days 2-3 is unexpected. There would appear to be a previously intrahepatic hemorrhage and rapid death. In principle, such in vivo toxicity might be reduced by directing the Fas triggering unappreciated kinetic difference between Fas-mediated apoptosis induction versus proliferative inhibition. Since the agents to the cell surfaces of cells within immune organs. However, it should be noted that Kupffer cells are B7 ϩ and, Fas receptor is up-regulated within 24 h of T cell activation 
